Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Papillomavirus Infections 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 176Rituximab 164fludarabine phosphate 97Peripheral Blood Stem Cell Transplantation 95Filgrastim 73Etoposide 67Radiotherapy 63Mycophenolic Acid 62Whole-Body Irradiation 58Tacrolimus 49Melphalan 49Cyclosporine 49Busulfan 47Lenalidomide 45Antilymphocyte Serum 39Vincristine 37Prednisone 37Cytarabine 37fludarabine 35Methotrexate 33Carmustine 32obinutuzumab 31Doxorubicin 30Bendamustine Hydrochloride 30Methylprednisolone 27ibritumomab tiuxetan 25Cord Blood Stem Cell Transplantation 25sargramostim 24Bortezomib 24Granulocyte Colony-Stimulating Factor 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Follicular × utomilumab × Clear all
NCT03636503 2025-02-06

Rituximab + Immunotherapy in Follicular Lymphoma

Dana-Farber Cancer Institute

Phase 1 Terminated
24 enrolled 25 charts
Lymphoid

Lymphoma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡